| Veröffentlichte Version Download ( PDF | 4MB) | Lizenz: Creative Commons Namensnennung 4.0 International |
Cyst growth in ADPKD is prevented by pharmacological and genetic inhibition of TMEM16A in vivo
Cabrita, Ines, Kraus, Andre, Scholz, Julia Katharina, Skoczynski, Kathrin, Schreiber, Rainer, Kunzelmann, Karl
und Buchholz, Björn
(2020)
Cyst growth in ADPKD is prevented by pharmacological and genetic inhibition of TMEM16A in vivo.
Nature Communications 11, S. 4320.
Veröffentlichungsdatum dieses Volltextes: 19 Feb 2021 09:48
Artikel
DOI zum Zitieren dieses Dokuments: 10.5283/epub.44976
Zusammenfassung
In autosomal dominant polycystic kidney disease (ADPKD) multiple bilateral renal cysts gradually enlarge, leading to a decline in renal function. Transepithelial chloride secretion through cystic fibrosis transmembrane conductance regulator (CFTR) and TMEM16A (anoctamin 1) are known to drive cyst enlargement. Here we demonstrate that loss of Pkd1 increased expression of TMEM16A and CFTR and Cl- ...
In autosomal dominant polycystic kidney disease (ADPKD) multiple bilateral renal cysts gradually enlarge, leading to a decline in renal function. Transepithelial chloride secretion through cystic fibrosis transmembrane conductance regulator (CFTR) and TMEM16A (anoctamin 1) are known to drive cyst enlargement. Here we demonstrate that loss of Pkd1 increased expression of TMEM16A and CFTR and Cl- secretion in murine kidneys, with TMEM16A essentially contributing to cyst growth. Upregulated TMEM16A enhanced intracellular Ca2+ signaling and proliferation of Pkd1-deficient renal epithelial cells. In contrast, increase in Ca2+ signaling, cell proliferation and CFTR expression was not observed in Pkd1/Tmem16a double knockout mice. Knockout of Tmeml6a or inhibition of TMEM16A in vivo by the FDA-approved drugs niclosamide and benzbromarone, as well as the TMEM16A-specific inhibitor Ani9 largely reduced cyst enlargement and abnormal cyst cell proliferation. The present data establish a therapeutic concept for the treatment of ADPKD.
Alternative Links zum Volltext
Beteiligte Einrichtungen
Details
| Dokumentenart | Artikel | ||||
| Titel eines Journals oder einer Zeitschrift | Nature Communications | ||||
| Verlag: | Nature | ||||
|---|---|---|---|---|---|
| Ort der Veröffentlichung: | BERLIN | ||||
| Band: | 11 | ||||
| Seitenbereich: | S. 4320 | ||||
| Datum | 28 August 2020 | ||||
| Institutionen | Biologie und Vorklinische Medizin > Institut für Physiologie > Prof. Dr. Karl Kunzelmann | ||||
| Identifikationsnummer |
| ||||
| Stichwörter / Keywords | KIDNEY-DISEASE; ANO1; CFTR; SECRETION; PROLIFERATION; ACTIVATION; EXPRESSION; | ||||
| Dewey-Dezimal-Klassifikation | 500 Naturwissenschaften und Mathematik > 570 Biowissenschaften, Biologie | ||||
| Status | Veröffentlicht | ||||
| Begutachtet | Ja, diese Version wurde begutachtet | ||||
| An der Universität Regensburg entstanden | Ja | ||||
| URN der UB Regensburg | urn:nbn:de:bvb:355-epub-449769 | ||||
| Dokumenten-ID | 44976 |
Downloadstatistik
Downloadstatistik